Immix Biopharma
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
11400 W Olympic Blvd, Los Angeles, Calif...Phone Number
(310) 651-8041Website
www.immixbio.comRevenue
<$5 MillionStock Symbol
IMMXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
2
1
1
About Immix Biopharma
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.Explore more
Immix Biopharma Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Immix Biopharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Immix Biopharma is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Immix Biopharma launches new products
Check if Immix Biopharma has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Immix Biopharma recently announced quarterly report
Funding: Get notified immidiatlly once Immix Biopharma has new funding data
Immix Biopharma, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Immix Biopharma had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Immix Biopharma
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Immix Biopharma
Compare insights from companies similar to Immix Biopharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Immix Biopharma is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Immix Biopharma is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Immix Biopharma.
Immix Biopharma financials insights
Gather financial insights about Immix Biopharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Share Placement
$5M
Immix Biopharma Tech Stack
A closer look at the technologies used by Immix Biopharma
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Person-Based
Person-Based
Funding
Immix Biopharma has secured an undisclosed amount in additional funding from investor GOOSE Capital.
Funding
Person-Based
Immix Biopharma News & Media
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
LOS ANGELES, May 21, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced the pricing of an underwritten registered offering of 16,778,524 shares of its common stock at a price to the public of $8.94 per share. The gross proceeds to Immix from the offering, before deducting the underwriting discounts, commissions and other offering expenses, are expected to be $150 million. TheImmix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
– Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) –Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
LOS ANGELES, CA, April 09, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will participate and host institutional investor meetings at the Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York, NY.Immix Biopharma completes NEXICART-2 enrollment | IMMX Stock News
Topline NEXICART-2 results are due in Q3 2026, followed by a planned BLA submission and launch. Immix also hired a former Merck and J&J executive as CMO.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Immix Biopharma
Sign Up For FreeTo access detailed company insights
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 fo... Read More
